Clinical phenotypes and age-related differences in SGLT2 inhibitor-associated ketoacidosis: A nationwide pharmacovigilance case-series study
With the expanding use of sodium-glucose cotransporter 2 inhibitors, pharmacovigilance data can help characterize rare but serious adverse drug reactions such as diabetic ketoacidosis. To describe the clinical spectrum and age-related differences in sodium-glucose cotransporter 2 inhibitor-associated ketoacidosis and identify distinct clinical presentation patterns using the French Pharmacovigilance Database. We conducted a retrospective nationwide case-series study including all expert-adjudicated reports of sodium-glucose cotransporter 2 inhibitor-associated ketoacidosis recorded in the French Pharmacovigilance Database up to December 31, 2025. Clinical characteristics were compared between patients aged < 65 and ≥ 65 years. Unsupervised clustering was used to identify clinical presentation patterns. Among 299 reports screened, 242 expert-adjudicated cases of ketoacidosis were included (median age 67 years [interquartile range 57–76]; 43% women), of which 88 (36%) fulfilled all three 2024 ADA/EASD diagnostic domains. Euglycemic DKA occurred in 64/165 patients with available blood glucose data (39%), moderate-to-severe metabolic acidosis in 107/177 patients with available pH data (60%), and 100/240 patients with available ICU data (42%) were admitted to an ICU. Three clinical presentation patterns were identified: (1) a fasting-related phenotype characterized by gastrointestinal symptoms and fasting; (2) a perioperative phenotype associated with recent surgery; and (3) an infection-related phenotype characterized by infection, neurological symptoms, and falls, predominantly affecting older patients. Neither moderate-to-severe acidosis nor ICU admission differed significantly between age groups. Sodium-glucose cotransporter 2 inhibitor-associated ketoacidosis shows heterogeneous presentations in routine practice. Older adults more often presented with atypical manifestations, whereas younger patients more often exhibited gastrointestinal symptoms. In older adults receiving sodium-glucose cotransporter 2 inhibitors, ketoacidosis should be considered when infection, neurological symptoms, or falls occur, even in the absence of gastrointestinal symptoms.
Authors
- Marie‐Laure Laroche (ORCID: https://orcid.org/0000-0003-4344-0359)
- Pierre‐Jean Saulnier (ORCID: https://orcid.org/0000-0003-1862-4252)
- Marion Allouchery (ORCID: https://orcid.org/0000-0002-8261-9549)
- Nassir Mirfendereski
- Bérenger Largeau (ORCID: https://orcid.org/0000-0002-6824-7283)
- Sophie Fédrizzi (ORCID: https://orcid.org/0009-0007-9331-8454)
- Marlène Damin‐Pernik (ORCID: https://orcid.org/0000-0001-5076-0698)
- Jean‐Luc Faillie (ORCID: https://orcid.org/0000-0003-0100-4073)
- Brahim Azzouz (ORCID: https://orcid.org/0000-0002-4395-2445)
- Héléna Mosbah (ORCID: https://orcid.org/0000-0001-7360-4209)
- Nathanaël Bassas Letissier (ORCID: https://orcid.org/0009-0005-7618-690X)
- Marc Paccalin (ORCID: https://orcid.org/0009-0008-3451-3097)
Institutions
- Université de Tours (FR)
- Inserm (FR)
- Université de Montpellier (FR)
- Université de Poitiers (FR)
- Centre Hospitalier Universitaire de Montpellier (FR)
- Centre Hospitalier Universitaire de Tours (FR)
- Centre Hospitalier Universitaire de Reims (FR)
- Laboratoire de Physique Corpusculaire de Caen (FR)
- Centre Hospitalier Universitaire de Poitiers (FR)
- Centre Hospitalier Universitaire de Caen Normandie (FR)
- Centre Hospitalier Universitaire de Limoges (FR)
- Services déconcentrés d'appui à la recherche Val de Loire (FR)
- Centre Hospitalier Universitaire de Saint-Étienne (FR)
- Membrane Signalling and Inflammation in reperfusion Injuries (FR)
- Université de Limoges (FR)
- Université de Reims Champagne-Ardenne (FR)
- Université de Caen Normandie (FR)
Publication Details
- Journal
- Aging Clinical and Experimental Research
- Published
- 2026-11-17
- DOI
- https://doi.org/10.1007/s40520-026-03566-2
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00